[go: up one dir, main page]

WO2002060339A3 - Ophthalmic compositions for treating ocular hypertension - Google Patents

Ophthalmic compositions for treating ocular hypertension Download PDF

Info

Publication number
WO2002060339A3
WO2002060339A3 PCT/US2002/002011 US0202011W WO02060339A3 WO 2002060339 A3 WO2002060339 A3 WO 2002060339A3 US 0202011 W US0202011 W US 0202011W WO 02060339 A3 WO02060339 A3 WO 02060339A3
Authority
WO
WIPO (PCT)
Prior art keywords
ocular hypertension
ophthalmic compositions
treating ocular
eye
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/002011
Other languages
French (fr)
Other versions
WO2002060339A2 (en
Inventor
Christine Stelmach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to EP02702069A priority Critical patent/EP1357855A2/en
Priority to US10/466,877 priority patent/US20040058976A1/en
Priority to CA002434485A priority patent/CA2434485A1/en
Priority to JP2002560536A priority patent/JP2004520379A/en
Publication of WO2002060339A2 publication Critical patent/WO2002060339A2/en
Publication of WO2002060339A3 publication Critical patent/WO2002060339A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)

Abstract

This invention relates a formulation comprising potent potassium channel blockers or pharmaceutically acceptable salts thereof in combination with peanut oil for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
PCT/US2002/002011 2001-01-30 2002-01-25 Ophthalmic compositions for treating ocular hypertension Ceased WO2002060339A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02702069A EP1357855A2 (en) 2001-01-30 2002-01-25 Ophthalmic compositions for treating ocular hypertension
US10/466,877 US20040058976A1 (en) 2002-01-25 2002-01-25 Ophthalmic compositions for treating ocular hypertension
CA002434485A CA2434485A1 (en) 2001-01-30 2002-01-25 Ophthalmic compositions for treating ocular hypertension
JP2002560536A JP2004520379A (en) 2001-01-30 2002-01-25 Ophthalmic composition for treatment of high intraocular pressure

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26495701P 2001-01-30 2001-01-30
US60/264,957 2001-01-30

Publications (2)

Publication Number Publication Date
WO2002060339A2 WO2002060339A2 (en) 2002-08-08
WO2002060339A3 true WO2002060339A3 (en) 2002-11-14

Family

ID=23008358

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/002011 Ceased WO2002060339A2 (en) 2001-01-30 2002-01-25 Ophthalmic compositions for treating ocular hypertension

Country Status (4)

Country Link
EP (1) EP1357855A2 (en)
JP (1) JP2004520379A (en)
CA (1) CA2434485A1 (en)
WO (1) WO2002060339A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003245531A1 (en) * 2002-06-17 2003-12-31 Merck & Co., Inc. Novel maxi-k channel blockers, methods of use and process for making the same
TNSN08110A1 (en) * 2008-03-11 2009-07-14 Rekik Raouf Dr Drug delivery to the anterior and posterior segment of the eye from drops

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573758A (en) * 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573758A (en) * 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers

Also Published As

Publication number Publication date
CA2434485A1 (en) 2002-08-08
EP1357855A2 (en) 2003-11-05
WO2002060339A2 (en) 2002-08-08
JP2004520379A (en) 2004-07-08

Similar Documents

Publication Publication Date Title
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007108968A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2003047513A3 (en) Method for treating ocular hypertension
WO2005020917A3 (en) Ophthalmic compositions for treating ocular hypertension
CA2505086A1 (en) Ophthalmic compositions for treating ocular hypertension
WO2002098350A3 (en) Pyranoindazoles and their use for the treatment of glaucoma
BRPI0413381A (en) compositions for releasing therapeutic compounds into the eyes and processes for the manufacture and use thereof
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
DK1553953T3 (en) A method and composition comprising latanoprost for the treatment of ocular hypertension and glaucoma
CA2440764A1 (en) Combination of brimonidine and timolol for topical ophthalmic use
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007120817A3 (en) Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
AU2003223224A1 (en) Compositions and methods for the treatment of glaucoma and ocular hypertension
BR0210238A (en) New Aryl-Amino-Propane Analogs and Their Use for the Treatment of Glaucoma
WO2007146136A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007127711A3 (en) Abnormal cannabidiols as agents for lowering intraocular pressure
ATE409491T1 (en) ORHTHALMOLOGICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSION
WO2004019874A3 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
WO2006020003A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2004028451A8 (en) β-HYDROXYPHENYLALKYLAMINES AND THEIR USE FOR TREATING GLAUCOMA
WO2004054572A3 (en) Novel benzopyran analogs and their use for the treatment of glaucoma
WO2002060339A3 (en) Ophthalmic compositions for treating ocular hypertension
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
WO2004087051A3 (en) Ophthalmic compositions for treating ocular hypertension
MXPA03010363A (en) Method for treating ocular hypertension and glaucoma.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002235454

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2434485

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10466877

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002560536

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002702069

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002702069

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002702069

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642